VAXINIA is under clinical development by Imugene and currently in Phase II for Kidney Cancer (Renal Cell Cancer). According to GlobalData, Phase II drugs for Kidney Cancer (Renal Cell Cancer) have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VAXINIA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VAXINIA (CF33+hNIS) is under development for the treatment of solid tumor, colon cancer, colorectal cancer, triple negative breast cancer, pancreatic cancer, non-small cell lung cancer, urothelial cancer, metastatic melanoma, bladder cancer, head and neck cancer, renal cell cancers and gastrointestinal cancer. It is administered through parenteral, intratumoral and intravenous routes. The drug candidate is a chimeric vaccinia, derived through a recombination of genetic sequences from multi pox virus strains. It comprises of oncolytic virus CF33 with the human sodium iodide symporter (hNIS).
Imugene is a clinical-stage biopharmaceutical company that focuses on the development of vaccines in the area of oncology immune. The company develops immunotherapies that activate the immune system of cancer patients to identify and eradicate tumors. The company’s pipeline products include HER-Vaxx, PD1-Vaxx, B-Vaxx, Vaxinia (CF33-hNIS), CHECKvacc (CF33+ hNIS+ PD-L1), PD-L1, VEGF, IGF-1R, HER-1, and HER-3 for the treatment of various tumors including gastric, breast, lung cancers. Imugene’s lead product candidate, CF33 is a chimeric vaccinia poxvirus for the treatment of mixed advanced solid tumors (MAST) and metastatic triple-negative breast cancer. It develops vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes recognized by an antibody with antitumor activity. Imugene is headquartered in Sydney, New South Wales Australia.
For a complete picture of VAXINIA’s drug-specific PTSR and LoA scores, buy the report here.